Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

JazzPharmaceuticals

More Like This

PR Newswire associated0

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024

PR Newswire associated0

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

PR Newswire associated0

Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024

PR Newswire associated0

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

PR Newswire associated0

Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023

PR Newswire associated0

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference